In such cases the identification of the mutated gene is of uppermost importance because first line treatment of RYR2 mutation-induced CPVT is based on beta blockers that can be less efficient on KCNJ2 mutated cases (Hayashi et al., 2009; Priori et al., 2013; Manzatti et al. 2020). The gene discussed is KCNJ2; the disease is catecholaminergic polymorphic ventricular tachycardia.